Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2021

01-01-2021 | Fenofibrate | Case report

Fenofibrate

Rhabdomyolysis: case report

Published in: Reactions Weekly | Issue 1/2021

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Tang Y, et al. Clinical Study and Literature Analysis of Rhabdomyolysis in Hypothyroidism Caused by Fenofibrate. [Chinese]. Chinese Pharmaceutical Journal 55: 1372-1375, No. 16, 22 Aug 2020. Available from: URL: http://​doi.​org/​10.​11669/​cpj.​2020.​16.​011 [Chinese; summarised from a translation]
Metadata
Title
Fenofibrate
Rhabdomyolysis: case report
Publication date
01-01-2021
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2021
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-89979-3

Other articles of this Issue 1/2021

Reactions Weekly 1/2021 Go to the issue

Case report

Low molecular weight heparins/warfarin

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Rituximab

Case report

Colchicine/methylprednisolone

Case report

Varicella zoster virus vaccine